|
|
|
|
|
Famciclovir
drug data and news
Famciclovir drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Famciclovir | ||
| Brand Names/Synonyms | CHEMBANK1696; FCV; Famciclovir; Famciclovir 98.5; Famciclovir [Usan:Ban:Inn]; Famciclovirum [Inn-Latin]; Famvir | ||
| Indication | For the treatment of acute herpes zoster (shingles); For the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Famciclovir is a prodrug that undergoes rapid biotransformation to the active antiviral compound penciclovir. Penciclovir is an anti-viral drug which has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella zoster virus (VZV). Therefore, herpes viral DNA synthesis and replication are selectively inhibited. | ||
| Mechanism Of Action | Famciclovir undergoes rapid biotransformation to the active antiviral compound penciclovir, which has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2) and varicella zoster virus (VZV). In cells infected with HSV-1, HSV-2 or VZV, viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted to penciclovir triphosphate by cellular kinases. In vitro studies demonstrate that penciclovir triphosphate inhibits HSV-2 DNA polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited. | ||
| Famciclovir News (When available) |
One-day, High-dose Famciclovir (Famvir) Therapy Cuts Healing Time ... 06 Mar 2006 Single-Dose Famvir(R) Treatment Found To Accelerate Healing Time ... Mar 3, 2006 Novartis: Strengthening Its Infectious Disease Portfolio Feb 9, 2006 Single-Day Famvir (Famciclovir) Treatment Found To Shorten the ... Jan 12, 2006 Novartis: strengthening its infectious disease portfolio Feb 7, 2006 Empiricus: our clinical journal commentator Jan 17, 2006 New Study Shows One Single Dose of Famvir Significantly Reduces ... Nov 9, 2005 Avaian flu threat to stimulate antiviral market growth Nov 11, 2005 e-coldsores.com Releases a Guide to Cold Sore Treatments Sep 29, 2005 Photo Quiz: Inflammatory Lesions on Every Finger Jul 31, 2005 Source: Ringling Bros. and Barnum & Bailey Jul 25, 2005 Common skin conditions and treatments Jun 16, 2005 Common skin conditions and treatments Jun 16, 2005 Merck's Shingles Vaccine Reduced Incidence, Severity and Duration ... Jun 4, 2005 Treatment for post-op swollen arm usually for life Apr 28, 2005 Treatment for post-op swollen arm usually for life 28 Apr 2005 | ||
| Dosage Forms | Tablet | ||
| Drug_Category | Prodrugs; Antivirals; Nucleosides and Nucleotides (08:18.32); ATC:J05AB09; ATC:S01AD07 | ||
| Absorption | 77% | ||
| Interactions |
Interactions for Famciclovir: Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir. The conversion of 6-deoxy penciclovir to penciclovir is catalyzed by aldehyde oxidase. Interactions with other drugs metabolized by this enzyme could potentially occur. | ||
| Toxicity | Constipation, diarrhea, dizziness, fatigue, fever, headache, nausea, vomiting | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | [2-(acetyloxymethyl)-4-(2-aminopurin-9-yl)-butyl] acetate | ||
| Chemical Formula | C14H19N5O4 | ||
| Molecular Weight | 321.332 g/mol | ||
| Smiles String | CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C | ||
| Melting Point | 102-104 °C | ||
| Water Solubility | Not Available | ||
| State | white to pale yellow solid | ||
| LogP/Hphobicity | 1.566 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Hepatic | ||
| Half Life | 10 hours | ||
| Protein Binding [%] | 20-25% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.rxlist.com/cgi/generic3/famciclovir.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00600 | ||
| CAS Registry Number | 104227-87-4 | ||
| KEGG Compound ID | D00317 | ||
| PubChem ID | SID:196284 | ||
| PharmGKB ID | PA449585 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2229110 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |